Markers of inflammation, oxidative stress, and endothelial dysfunction and the 20-year cumulative incidence of early age-related macular degeneration: the Beaver Dam Eye Study
- PMID: 24481424
- PMCID: PMC4076038
- DOI: 10.1001/jamaophthalmol.2013.7671
Markers of inflammation, oxidative stress, and endothelial dysfunction and the 20-year cumulative incidence of early age-related macular degeneration: the Beaver Dam Eye Study
Abstract
IMPORTANCE Modifying levels of factors associated with age-related macular degeneration (AMD) may decrease the risk for visual impairment in older persons. OBJECTIVE To examine the relationships of markers of inflammation, oxidative stress, and endothelial dysfunction to the 20-year cumulative incidence of early AMD. DESIGN, SETTING, AND PARTICIPANTS This longitudinal population-based cohort study involved a random sample of 975 persons in the Beaver Dam Eye Study without signs of AMD who participated in the baseline examination in 1988-1990 and up to 4 follow-up examinations in 1993-1995, 1998-2000, 2003-2005, and 2008-2010. EXPOSURES Serum markers of inflammation (high-sensitivity C-reactive protein, tumor necrosis factor-α receptor 2, interleukin-6, and white blood cell count), oxidative stress (8-isoprostane and total carbonyl content), and endothelial dysfunction (soluble vascular cell adhesion molecule-1 and soluble intercellular adhesion molecule-1) were measured. Interactions with complement factor H (rs1061170), age-related maculopathy susceptibility 2 (rs10490924), complement component 3 (rs2230199), and complement component 2/complement factor B (rs4151667) were examined using multiplicative models. Age-related macular degeneration was assessed from fundus photographs. MAIN OUTCOMES AND MEASURES Early AMD defined by the presence of any size drusen and the presence of pigmentary abnormalities or by the presence of large-sized drusen (≥125-μm diameter) in the absence of late AMD. RESULTS The 20-year cumulative incidence of early AMD was 23.0%. Adjusting for age, sex, and other risk factors, high-sensitivity C-reactive protein (odds ratio comparing fourth with first quartile, 2.18; P = .005), tumor necrosis factor-α receptor 2 (odds ratio, 1.78; P = .04), and interleukin-6 (odds ratio, 1.78; P = .03) were associated with the incidence of early AMD. Increased incidence of early AMD was associated with soluble vascular cell adhesion molecule-1 (odds ratio per SD on the logarithmic scale, 1.21; P = .04). CONCLUSIONS AND RELEVANCE We found modest evidence of relationships of serum high-sensitivity C-reactive protein, tumor necrosis factor-α receptor 2, interleukin-6, and soluble vascular cell adhesion molecule-1 to the 20-year cumulative incidence of early AMD independent of age, smoking status, and other factors. It is not known whether these associations represent a cause and effect relationship or whether other unknown confounders accounted for the findings. Even if inflammatory processes are a cause of early AMD, it is not known whether interventions that reduce systemic inflammatory processes will reduce the incidence of early AMD.
Conflict of interest statement
Figures


Similar articles
-
Progression of age-related macular degeneration: prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers.Arch Ophthalmol. 2005 Jun;123(6):774-82. doi: 10.1001/archopht.123.6.774. Arch Ophthalmol. 2005. PMID: 15955978
-
Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study.Ophthalmology. 2007 Feb;114(2):253-62. doi: 10.1016/j.ophtha.2006.10.040. Ophthalmology. 2007. PMID: 17270675
-
Incidence and progression of reticular drusen in age-related macular degeneration: findings from an older Australian cohort.Ophthalmology. 2014 Apr;121(4):917-25. doi: 10.1016/j.ophtha.2013.10.043. Epub 2013 Dec 12. Ophthalmology. 2014. PMID: 24332537
-
Relation of smoking to the incidence of age-related maculopathy. The Beaver Dam Eye Study.Am J Epidemiol. 1998 Jan 15;147(2):103-10. doi: 10.1093/oxfordjournals.aje.a009421. Am J Epidemiol. 1998. PMID: 9456998 Review.
-
Age-related macular degeneration.Nat Rev Dis Primers. 2021 May 6;7(1):31. doi: 10.1038/s41572-021-00265-2. Nat Rev Dis Primers. 2021. PMID: 33958600 Review.
Cited by
-
Metabolic activity of visceral adipose tissue is associated with age-related macular degeneration: a pilot 18F-FDG PET/CT study.Front Endocrinol (Lausanne). 2024 Jan 8;14:1322326. doi: 10.3389/fendo.2023.1322326. eCollection 2023. Front Endocrinol (Lausanne). 2024. PMID: 38260144 Free PMC article.
-
High-Fat Diet Alters the Retinal Pigment Epithelium and Choroidal Transcriptome in the Absence of Gut Microbiota.Cells. 2022 Jun 30;11(13):2076. doi: 10.3390/cells11132076. Cells. 2022. PMID: 35805160 Free PMC article.
-
Glucose Metabolic Characterization of Human Aqueous Humor in Relation to Wet Age-Related Macular Degeneration.Invest Ophthalmol Vis Sci. 2020 Mar 9;61(3):49. doi: 10.1167/iovs.61.3.49. Invest Ophthalmol Vis Sci. 2020. PMID: 32232346 Free PMC article.
-
Age-related macular degeneration: insights into inflammatory genes.J Ophthalmol. 2014;2014:582842. doi: 10.1155/2014/582842. Epub 2014 Nov 12. J Ophthalmol. 2014. PMID: 25478207 Free PMC article. Review.
-
Intravenous route to choroidal neovascularization by macrophage-disguised nanocarriers for mTOR modulation.Acta Pharm Sin B. 2022 May;12(5):2506-2521. doi: 10.1016/j.apsb.2021.10.022. Epub 2021 Oct 28. Acta Pharm Sin B. 2022. PMID: 35646523 Free PMC article.
References
-
- Ferris FL, III, Tielsch JM. Blindness and visual impairment: a public health issue for the future as well as today. Arch Ophthalmol. 2004;122(4):451–452. - PubMed
-
- Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122(4):564–572. - PubMed
-
- Congdon N, O'Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122(4):477–485. - PubMed
-
- Haddad S, Chen CA, Santangelo SL, Seddon JM. The genetics of age-related macular degeneration: a review of progress to date. Surv Ophthalmol. 2006;51(4):316–363. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials